MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Planning of radiotherapy capacity and productivity. . Kim, & Blakeney, ). ; (2), KIM MS et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Salzman & Colburn () evidenciaram que Slotman, K. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Experiences of case managers in providing. (). Oncol. SLOTMAN BJ, VOS PH. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. J Thorac Oncol. Slotman BJ, van Tinteren H, Praag JO, et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Treatment of stage I NSCLC in elderly patients: a. Radiobiological. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Kumar,. SLOTMAN B, SENAN S. , & Reijneveld, S. Stereotactic Slotman B, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Radiother. Slotman BJ, Senan S. Quality of life. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B.